A licensed physician reviews your medical history, current medications, and specific situation before designing your protocol. Sexual concerns are sensitive and often multifactorial — your physician treats them that way.
PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder (as Vyleesi) and used clinically off-label for arousal and desire concerns in both men and women. Every batch independently lab-tested.
Monthly subscription. Discreet packaging. Manage, pause, or cancel through your dashboard. Message your care team anytime with questions — your physician is reachable through the app.
PT-141 (Bremelanotide) is mechanistically distinct from vasodilator medications. It works upstream of the physical response, on the brain pathways involved in desire and arousal.
PT-141 activates melanocortin receptors (MC3 and MC4) in central nervous system pathways involved in sexual arousal. Mechanistically distinct from PDE5 inhibitors like Viagra or Cialis, which work peripherally on blood flow.
PDE5 inhibitors enhance the physical response to existing arousal. PT-141 affects the desire and arousal pathways themselves — useful when the primary issue isn't blood flow but the upstream signal.
PT-141 is administered as a subcutaneous injection 30–60 minutes before intended sexual activity. Effects build over hours and persist for several hours. Each use is independent — no daily protocol building over time.
PT-141 is a different drug class from PDE5 inhibitors. We don't pretend it's a universal answer — your physician evaluates whether the mechanism fits your specific situation before prescribing.
Sexual concerns are often multifactorial — hormonal, psychological, medication-related, relational. Your physician evaluates the full picture and is honest when PT-141 isn't the right starting point.
Your information stays confidential and is reviewed only by your physician. Shipments arrive in discreet packaging. Care-team messaging is private and clinical — the same standard we hold every other program to.